Well-Studied

Supported by multiple clinical trials and systematic reviews

Menopause Symptoms

Menopause is a natural life stage defined retrospectively after 12 months without a menstrual period, typically occurring around age 51. The years leading up to the final menstrual period (perimenopause) feature fluctuating ovarian hormone production, especially estrogen and progesterone, which drives many symptoms. Common complaints include vasomotor symptoms (hot flashes and night sweats), sleep disturbance, mood changes, brain fog, genitourinary syndrome of menopause (vaginal dryness, discomfort with sex, urinary urgency), joint aches, and weight/body composition shifts. Risk for bone loss accelerates, and cardiometabolic risk often increases with aging, body fat redistribution, and changing lipid/glucose profiles. Western medicine evaluates menopause through history and cycle pattern (formal hormone testing is usually unnecessary in typical midlife unless the diagnosis is uncertain or menopause is early/premature). Management is individualized by symptom burden, time since menopause, age, personal and family history (breast cancer, venous thromboembolism, stroke, cardiovascular disease), and patient preferences. Systemic menopausal hormone therapy (HT)—estrogen alone for women without a uterus or estrogen plus progestogen for those with a uterus—remains the most effective therapy for vasomotor symptoms and also prevents bone loss while in use. Contemporary interpretations of the Women’s Health Initiative (WHI) and subsequent analyses support the “timing hypothesis”: for healthy, symptomatic women who initiate HT within 10 years of the final menstrual period or before age 60, the benefit–risk profile is favorable when appropriately selected and dosed. Transdermal estradiol and micronized progesterone are often preferred to reduce thrombotic and some metabolic risks. HT is not indicated for primary prevention of cardiovascular disease or dementia and is generally avoided in women with a history of estrogen-sensitive cancers, unexplained vaginal bleeding, active/h

Women’s Health Updated March 13, 2026

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication regimen.

Western Medicine

Diagnosis

Clinical diagnosis guided by symptom history and menstrual pattern using frameworks such as STRAW+10 staging. Menopause is defined after 12 months of amenorrhea not explained by other causes. Labs (FSH/estradiol) are usually unnecessary but may help in unclear cases, suspected premature ovarian insufficiency, or after hysterectomy without oophorectomy. Differential diagnosis for hot flashes/sweats includes thyroid disease, infection, medication effects, and anxiety. Baseline risk assessment includes breast cancer, VTE, stroke, ASCVD risk, bone health, and mood/sleep screening.

Treatments

Lifestyle and education: trigger management for hot flashes (heat, alcohol), layering clothing, paced breathing; sleep hygiene; exercise; weight management; alcohol moderation; smoking cessation
Systemic hormone therapy (HT): 17β-estradiol (transdermal/oral) ± progestogen (micronized progesterone or levonorgestrel IUD for endometrial protection); consider timing hypothesis (start <60 years or within 10 years of menopause)
Local therapy for genitourinary syndrome of menopause (GSM): low-dose vaginal estrogen (cream, tablet, ring), vaginal DHEA (prasterone), or oral ospemifene; nonhormonal moisturizers/lubricants
Nonhormonal options for vasomotor symptoms: fezolinetant (NK3 receptor antagonist); SSRIs/SNRIs (paroxetine 7.5 mg, venlafaxine, desvenlafaxine, escitalopram, citalopram); gabapentin; oxybutynin; (clonidine less favored)
Mood and cognitive concerns: CBT for hot flash distress, anxiety/depression management; treat sleep disruption (CBT-I); HT is not indicated to prevent cognitive decline/dementia
Bone health: calcium and vitamin D adequacy, resistance/impact exercise, fall prevention; consider DXA screening per guidelines; pharmacotherapy (bisphosphonates, denosumab, or others) when indicated; HT prevents bone loss while used
Cardiometabolic risk reassessment: manage blood pressure, lipids, glucose; consider transdermal estrogen and the lowest effective dose to minimize risk; HT not for CV prevention
Sexual health: address pain, desire/libido, pelvic floor therapy; consider local estrogen/DHEA or ospemifene; treat comorbid depression/anxiety and relationship factors

Medications

Estradiol (transdermal patch/gel/spray; oral estradiol)
Conjugated estrogens (oral; often with bazedoxifene as a tissue-selective estrogen complex)
Micronized progesterone (oral), dydrogesterone (varies by region), levonorgestrel IUD for endometrial protection
Fezolinetant (NK3 receptor antagonist)
Paroxetine 7.5 mg (Brisdelle), venlafaxine, desvenlafaxine, escitalopram, citalopram
Gabapentin (particularly for nocturnal vasomotor symptoms)
Oxybutynin (selected cases)
Low-dose vaginal estrogen (estradiol or conjugated estrogens), vaginal DHEA (prasterone), ospemifene
Bone agents: bisphosphonates, denosumab; calcium/vitamin D as adjuncts

Limitations

HT requires individualized risk–benefit assessment and is generally avoided in women with a history of estrogen-sensitive malignancy, prior VTE/stroke, active liver disease, or unexplained vaginal bleeding. Risks vary by age, time since menopause, route, dose, and progestogen choice. Nonhormonal agents have variable efficacy and class-specific side effects (e.g., SSRIs/SNRIs: nausea/sexual dysfunction; gabapentin: dizziness/somnolence; oxybutynin: anticholinergic effects). Long-term fezolinetant safety is being further characterized. Vaginal estrogen has minimal systemic absorption but oncologic safety should be co-managed with the oncology team in breast cancer survivors. HT does not prevent cognitive decline and late initiation (>10 years since menopause or age >60–65) may carry higher risk. Evidence for some lifestyle/mind-body therapies is strongest for symptom distress and sleep rather than reducing hot flash frequency.

Evidence: Strong Evidence

Sources

North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement.
NAMS. Nonhormone therapy position statement for vasomotor symptoms (2023).
Manson JE et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: WHI 18-year follow-up. JAMA. 2017.
Rossouw JE et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: WHI. JAMA. 2002; with subsequent reanalyses emphasizing age/timing effects.
NAMS/ISSWSH. 2020 consensus recommendations on genitourinary syndrome of menopause (GSM).
Phase 3 SKYLIGHT 1 and 2 trials of fezolinetant for vasomotor symptoms. Lancet/JAMA, 2023.
MsFLASH network RCTs of SSRIs/SNRIs, gabapentin for vasomotor symptoms, 2011–2016.
Women’s Health Initiative Memory Study (WHIMS): late-life HT and dementia risk in women ≥65 years.

Eastern & Traditional Medicine

Traditional Chinese Medicine (TCM) framework

Perimenopause is often interpreted as kidney yin deficiency with relative deficiency heat causing hot flashes/night sweats, sometimes with liver qi stagnation contributing to irritability and sleep disturbance. Treatment principles: nourish kidney yin, clear deficiency heat, anchor yang, and smooth liver qi. Patterns are individualized.

Techniques

Acupuncture point prescriptions commonly including KI3, SP6, LR3, HT6, REN4, DU20; ear acupuncture or electroacupuncture in some protocols
Chinese herbal formulas such as Liu Wei Di Huang Wan (Rehmannia Six) and Zhi Bai Di Huang Wan (adds Anemarrhena/Phellodendron for heat); alternatives include Er Xian Tang or You Gui Wan depending on pattern
Dietary/lifestyle advice per TCM (cooling foods, stress reduction, qigong/taichi)

Licensed acupuncturist/TCM practitioner Integrative medicine physician with TCM training

Evidence: Moderate Evidence

Acupuncture (focused evidence for vasomotor symptoms)

Course-based acupuncture (6–12 sessions over ~6–8 weeks) can reduce hot flash frequency and improve sleep/quality of life. Effects vs sham are modest but clinically meaningful for some; effects vs waitlist/usual care are larger.

Techniques

Body acupuncture with standardized or individualized point sets; some trials use electroacupuncture
Adjunctive acupressure/home practice

Licensed acupuncturist Medical acupuncturist

Evidence: Moderate Evidence

Chinese herbal medicine

Pattern-based prescriptions aim to nourish yin and clear deficiency heat. Liu Wei Di Huang Wan and Zhi Bai Di Huang Wan are commonly used; Er Xian Tang has been studied for vasomotor symptoms and mood.

Techniques

Classical formulas adjusted to pattern; quality-controlled, practitioner-prescribed products preferred
Monitoring for herb–drug interactions and liver function when indicated

TCM herbalist/physician

Evidence: Emerging Research

Ayurveda

Menopause (rajonivritti) often reflects vata–pitta imbalance. Approaches include diet, routine, yoga/pranayama, and rasayana herbs to support resilience. Shatavari (Asparagus racemosus) is used for vasomotor and urogenital dryness; Ashwagandha (Withania somnifera) targets stress, sleep, and mood.

Techniques

Standardized extracts of Shatavari or Ashwagandha under practitioner guidance
Abhyanga (oil massage), yoga, pranayama, meditation; individualized diet/lifestyle

Ayurvedic practitioner Integrative clinician familiar with Ayurvedic botanicals

Evidence: Emerging Research

Sources

Cochrane Review: Acupuncture for vasomotor menopausal symptoms (2013) – mixed/limited but suggestive evidence.
Chiu HY et al. Acupuncture to reduce hot flashes in menopausal women: systematic review and meta-analysis. Menopause. 2015.
Avis NE et al. MsFLASH acupuncture trial: reductions in hot flash frequency vs wait-list/usual care. Menopause. 2016.
Cochrane Review: Chinese herbal medicines for menopausal symptoms (2012; updated analyses) – heterogenous evidence, quality concerns, some potential benefit in selected formulas.
Cochrane Review (2013): acupuncture for hot flashes – low-to-moderate quality, small benefit vs sham, greater vs no treatment.
Recent meta-analyses (2015–2019) report small-to-moderate reductions in hot flash frequency and severity, improved sleep.
Cochrane Review: Chinese herbal medicines for menopause (2012; updates) – heterogeneity and risk of bias limit conclusions; some trials suggest benefit.
Selected RCTs of Er Xian Tang report hot flash and mood improvements vs placebo/usual care; replication and quality assurance needed.
Small RCTs and open-label studies of Shatavari suggest improvements in vasomotor and urogenital symptoms; methodological limitations exist.
Ashwagandha RCTs show reductions in stress/anxiety and improved sleep in midlife adults; limited menopause-specific trials.

Integrative Perspective

A personalized plan can combine first-line, evidence-based Western therapies with selected complementary approaches for additive benefit and patient preference. For healthy, symptomatic women within 10 years of the final menstrual period, systemic HT remains the most effective vasomotor therapy and also supports bone while in use. Many women add nonhormonal strategies—CBT for hot flash distress and sleep, acupuncture for additional vasomotor relief, yoga/mindfulness for mood and sleep, and vaginal moisturizers/lubricants for GSM. If systemic HT is not desired or contraindicated, nonhormonal pharmacologic options (fezolinetant, SSRIs/SNRIs, gabapentin) can be paired with acupuncture, mind–body therapies, and, when appropriate, dietary phytoestrogens. For GSM, low-dose vaginal estrogen or vaginal DHEA is often the most effective and can be safely combined with lubricants, pelvic floor therapy, and sexual counseling. Safety distinctions matter. Phytoestrogens (e.g., soy isoflavones, red clover) are plant compounds with weak estrogenic activity; foods are generally safe for most women, including breast cancer survivors, while concentrated supplements show mixed efficacy and should be used cautiously with oncology input. FDA-approved "bioidentical" hormones (such as transdermal 17β-estradiol and oral micronized progesterone) meet quality and safety standards; in contrast, compounded bioidentical hormone products are not FDA-approved, may have variable dosing/purity, lack large safety trials, and are generally not recommended when approved alternatives exist. Work with qualified practitioners, disclose all supplements/therapies to coordinate care, and periodically reassess symptom control, risks, and goals as needs evolve.

Sources

North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement.
NAMS. Nonhormone therapy position statement for vasomotor symptoms (2023).
Women’s Health Initiative (WHI): original and updated analyses emphasizing age/timing effects (e.g., Manson JE et al., JAMA 2017).
NAMS/ISSWSH consensus on genitourinary syndrome of menopause (2020).
Phase 3 SKYLIGHT trials of fezolinetant for vasomotor symptoms (2023).
Cochrane Review: Acupuncture for vasomotor menopausal symptoms (2013).
Cochrane Review: Phytoestrogens for vasomotor menopausal symptoms (Lethaby et al., 2013).
Cochrane Review: Black cohosh for menopausal symptoms (Leach & Moore, 2012).
Systematic reviews/meta-analyses 2015–2019 on acupuncture for menopause; MENOS CBT trials; clinical hypnosis RCTs for hot flashes.

Menopause Symptoms

Western Medicine

Diagnosis

Treatments

Medications

Limitations

Eastern & Traditional Medicine

Traditional Chinese Medicine (TCM) framework

Techniques

Acupuncture (focused evidence for vasomotor symptoms)

Techniques

Chinese herbal medicine

Techniques

Ayurveda

Techniques

Integrative Perspective

Sources

Recommended Products

The Menopause Manifesto: Own Your Health with Facts and Feminism: Dr. Jen Gunter

Nature's Way Soy Isoflavones, Menopause Symptom Relief Support*, 100mg of Soybean Extract Per Serving, 60 Vegan Capsules

Good Clean Love Rehydrate Ultra Moisturizing Vaginal Gel with Hyaluronic Acid, pH-Balanced Vaginal Moisturizer, Water-Based Feminine Care, Long Lasting Relief from Dryness & Discomfort, 2 Oz

Related Content

Osteoporosis and Menopause

Endometriosis and Infertility

Polycystic Ovary Syndrome (PCOS): East vs West

Iron Deficiency Without Anemia: Fatigue, Ferritin, and Finding Balance

Telomere Length and Lifestyle: What Really Matters for Healthy Aging

Burnout and Adrenal Health: What the Science Really Says About HPA Axis Dysregulation and Adaptogens